| 1 |
33820447 | Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. | 2021 Jun |
1 |
| 2 |
33917617 | Aryl Urea Based Scaffolds for Multitarget Drug Discovery in Anticancer Immunotherapies. | 2021 Apr 6 |
1 |
| 3 |
33925488 | Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment. | 2021 Apr 27 |
5 |
| 4 |
34208001 | Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells. | 2021 Jun 11 |
3 |
| 5 |
34771459 | Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. | 2021 Oct 22 |
1 |
| 6 |
35117990 | Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection. | 2021 |
2 |
| 7 |
32560747 | Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells. | 2020 Dec 10 |
14 |
| 8 |
33000204 | KCNQ1OT1 contributes to sorafenib resistance and programmed death‑ligand‑1‑mediated immune escape via sponging miR‑506 in hepatocellular carcinoma cells. | 2020 Nov |
2 |
| 9 |
33163195 | Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells. | 2020 Oct |
5 |
| 10 |
33221703 | LncRNA MIAT correlates with immune infiltrates and drug reactions in hepatocellular carcinoma. | 2020 Dec |
1 |
| 11 |
31019901 | Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. | 2019 Mar |
7 |
| 12 |
27913861 | CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia. | 2017 Feb |
1 |
| 13 |
28627705 | Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. | 2017 Aug |
6 |